A composition including an elastin-like polypeptide (ELP) coupled to a kidney targeting peptide and. a therapeutic agent is provided. A method of delivering a therapeutic agent to a subject in need thereof comprising: administering to the subject an effective amount of a composition comprising: an elastin-like polypeptide (ELP), a kidney targeting agent coupled to the ELP and a targeting agent and/or a drug binding domain coupled to the ELP, wherein the ELP includes an amino acid sequence having at least about repeats of the amino acid sequence GVPGX (SEQ ID NO: 1), and wherein the composition enhances the deposition and retention of the therapeutic agent in the kidney relative to the non-conjugated therapeutic.

The present invention provides nucleic acid constructs, expression vectors, transgenic cell and methods of making and using the same, wherein the nucleic acid construct includes a synthetic promoter designed from the endogenous promoter of BIRC5 and LAMC2. In illustrative working embodiments of the invention, an exogenous nucleic acid fragment encoding thymidine kinase is operably linked to the synthetic promoter which is then shown to regulate the expression of this polypeptide.

The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

The present invention provides therapeutic agents and compositions comprising elastin-like peptides (ELPs) and therapeutic proteins. In some embodiments, the therapeutic protein is a GLP-1 receptor agonist, insulin, or Factor VII/VIIa, including functional analogs. The present invention further provides encoding polynucleotides, as well as methods of making and using the therapeutic agents. The therapeutic agents have improvements in relation to their use as therapeutics, including, inter alia, one or more of half-life, clearance and/or persistance in the body, solubility, and bioavailability.

The present invention relates to a CHO cell-derived protein secretory factor, an expression cassette in which a nucleic acid sequence encoding the protein secretory factor; and a gene encoding a target protein are operably linked, an expression vector comprising the expression cassette, a transformed cell into which the expression vector is introduced, and a method for producing a target protein using the transformed cell.

The present invention relates to a CHO cell-derived protein secretory factor, an expression cassette in which a nucleic acid sequence encoding the protein secretory factor; and a gene encoding a target protein are operably linked, an expression vector comprising the expression cassette, a transformed cell into which the expression vector is introduced, and a method for producing a target protein using the transformed cell.

The present invention discloses immunogenic compositions including recombinant peptides and proteins comprising human immunodeficiency viruses (HIV) antigens and immunogens, e.g., gp 120 protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble HIV viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing an HIV infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

The present invention discloses immunogenic compositions including recombinant peptides and proteins comprising human immunodeficiency viruses (HIV) antigens and immunogens, e.g., gp 120 protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble HIV viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing an HIV infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits.

The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.

The present invention refers to a composition comprising a solution which in turn comprises an amino acidic chain gelatin polymer derived from natural sources of cold-adapted marine species, at a concentration from 1% to 20% (w/v), which optionally further comprises a polymerizing initiator such as a photoinitiator, and is chemically functionalized to become reactive to polymerization or crosslinking in presence of free radicals. This composition is especially useful for 3D printing, extrusion systems (additive fabrication), spray systems, casting, micro- and nano fibers fabrication systems (electrospinning, solution blow spinning) or microfluidics.